ZA200800116B - New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis - Google Patents

New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis

Info

Publication number
ZA200800116B
ZA200800116B ZA200800116A ZA200800116A ZA200800116B ZA 200800116 B ZA200800116 B ZA 200800116B ZA 200800116 A ZA200800116 A ZA 200800116A ZA 200800116 A ZA200800116 A ZA 200800116A ZA 200800116 B ZA200800116 B ZA 200800116B
Authority
ZA
South Africa
Prior art keywords
fibrotic
liver fibrosis
new combination
caspase inhibitor
madcam antibody
Prior art date
Application number
ZA200800116A
Other languages
English (en)
Inventor
Burgess Gary Craig
Kerry Roger
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of ZA200800116B publication Critical patent/ZA200800116B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200800116A 2005-07-11 2008-01-04 New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis ZA200800116B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69856105P 2005-07-11 2005-07-11

Publications (1)

Publication Number Publication Date
ZA200800116B true ZA200800116B (en) 2008-12-31

Family

ID=37434222

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800116A ZA200800116B (en) 2005-07-11 2008-01-04 New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis

Country Status (15)

Country Link
US (1) US20090214527A1 (fr)
EP (1) EP1904100A1 (fr)
JP (1) JP2007023030A (fr)
KR (1) KR20080017094A (fr)
CN (1) CN101217980A (fr)
AR (1) AR054828A1 (fr)
AU (1) AU2006267976B2 (fr)
BR (1) BRPI0613459A2 (fr)
CA (1) CA2614622A1 (fr)
IL (1) IL188397A0 (fr)
MX (1) MX2008000659A (fr)
RU (1) RU2008101383A (fr)
TW (1) TW200730190A (fr)
WO (1) WO2007007162A1 (fr)
ZA (1) ZA200800116B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2362667T3 (es) * 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
US20080070823A1 (en) * 2006-09-15 2008-03-20 Philip Gorlin Liquid Detergent Composition
ES2524021T3 (es) * 2006-12-06 2014-12-03 Conatus Pharmaceuticals, Inc. Formas cristalinas del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico
WO2008106167A1 (fr) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
US8642558B2 (en) 2008-09-19 2014-02-04 Henry Ford Health Systems Methods, systems, and compositions for calpain inhabition
WO2012021800A2 (fr) * 2010-08-13 2012-02-16 Banyan Biomarkers Inhibiteurs de la caspase utilisés comme agents thérapeutiques contre une lésion neurale ou d'organe et pour l'imagerie
EP3456711A4 (fr) * 2016-05-11 2019-10-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Inhibiteur de caspase et composition pharmaceutique, utilisation et procédé thérapeutique associés
EP3652211A1 (fr) * 2017-07-14 2020-05-20 Pfizer Inc. Anticorps dirigés contre madcam

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2004081049A1 (fr) * 2003-03-10 2004-09-23 Auckland Uniservices Limited Anticorps monoclonaux reconnaissant la molecule d'adherence cellulaire d'adressine des muqueuses, forme soluble de madcam-1, et utilisations
ES2362667T3 (es) * 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
PE20070374A1 (es) * 2005-07-08 2007-05-12 Pfizer Ltd ANTICUERPOS ANTI-MAdCAM

Also Published As

Publication number Publication date
EP1904100A1 (fr) 2008-04-02
AU2006267976A1 (en) 2007-01-18
IL188397A0 (en) 2008-08-07
WO2007007162A1 (fr) 2007-01-18
KR20080017094A (ko) 2008-02-25
RU2008101383A (ru) 2009-07-20
JP2007023030A (ja) 2007-02-01
AR054828A1 (es) 2007-07-18
CA2614622A1 (fr) 2007-01-18
MX2008000659A (es) 2008-03-13
CN101217980A (zh) 2008-07-09
AU2006267976B2 (en) 2009-12-24
US20090214527A1 (en) 2009-08-27
TW200730190A (en) 2007-08-16
BRPI0613459A2 (pt) 2011-01-11

Similar Documents

Publication Publication Date Title
ZA200800116B (en) New combination of anti-MAdCAM antibody and anti-fibrotic caspase inhibitor to treat liver fibrosis
EP1883406A4 (fr) Compositions et procedes pour la liberation prolongee de beta-alanine
HK1120160A1 (en) Trenched-gate field effect transistors and methods of forming the same
IL189795A0 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
IL185914A0 (en) Pyrimidine compounds and methods of use
BRPI0615224A2 (pt) redução de esteróis e de outros compostos em óleos
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
IL191072A0 (en) Therapeutic compositions and methods
EP1951278A4 (fr) Methodes et compositions destinees a la derepression d'une caspase inhibee par iap
IL187304A0 (en) Pyrrolopyridine - based inhibitors of dipeptidyl peptidase iv and methods
ZA200805296B (en) Allergy inhibitor compositions and kits and methods of using the same
IL177709A0 (en) Caspase inhibitors and uses thereof
IL182943A0 (en) Ovr110 antibody compositions and methods of use
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP1763346A4 (fr) Composition et methodes se rapportant aux inhibiteurs de la synthese de la pyrimidine
EP1937075A4 (fr) Composition synergique et procede d'utilisation
EP1933805A4 (fr) Compositions anti-inflammatoires et procédés d utilisation
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
EP1912630A4 (fr) Compositions et procedes destines a reduire les douleurs postoperatoires
GB0520930D0 (en) Composition and method of use
PL2572724T3 (pl) Leczenie zwłóknień i chorób wątroby
ZA200804710B (en) Treatment and prevention of adverse liver conditions using gallium
EP1940458A4 (fr) Compositions et procedes d'inhibition du granzyme b
EP1912633A4 (fr) Methodes et compositions destinees a inhiber la permeabilite vasculaire